课题基金 / 基金详情

Development of new immune cell therapies with human leukemia model mouse.

Development of new immune cell therapies with human leukemia model mouse.
利用人类白血病模型小鼠开发新的免疫细胞疗法。
批准号:
12557078
负责人:
MITANI Kinuko
金额:
$7.49万
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (B)
财政年份:
2000
资助国家:
日本
项目状态:
已结题
起止时间:
2000 至 2003

项目摘要

项目成果

MITANI Kinuko的其他基金

相似基金

相关文献

中文摘要
翻译
1.AML1/EVI-1是一种嵌合转录因子,在慢性髓性白血病(CML)和骨髓增生异常综合征(MDS)的成母细胞转化中起致病作用。AML1/EVI-1通过被TGFI3信号激活的pai -1启动子抑制转录。AML1/ evi -1特异性结合TGFβ细胞内信号传感器Smad3,并抑制其功能。由于AMLI/EVI-1结合了一个辅助抑制因子CtBP,组蛋白去乙酰化酶的募集可能是一个潜在的机制。AML1/EVI-1也通过与CtBP的关联干扰AMIL -1介导的转录。此外,AML1/ evi - 1阻断G-CSF诱导的32D细胞分化,这取决于evi - 1部分的ctbp结合区域。这些数据表明,AMLI/ evi -1部分通过消除TGFβ信号和阻断AML1功能将CML或MIDS进展为急性白血病。我们使用诱导性基因靶向方法评估了成人造血中AML 1的需求。在没有AML 1的情况下,造血祖细胞完全维持正常的髓细胞发育。然而,AML 1缺陷骨髓显示巨核细胞成熟抑制,造血祖细胞增加,t淋巴细胞和b淋巴细胞发育缺陷。这些数据表明,AML1对于巨核细胞的成熟和T细胞和B细胞的分化是必需的,但对于成人造血干细胞的维持不是必需的。我们产生了MEN基因敲除小鼠。胚胎死亡,在E6.5前和着床后死亡。研究发现,在小鼠植入后发育过程中,MEN作为一种延伸因子发挥着非冗余的作用。
英文摘要
1.AML1/EVI-1 is a chimeric transcription factor that plays a causative role in blastic transformation of chronic myelogenous leukemia (CML) and myelodysplastic syndrome (MDS). AML1/EVI-1 repressed transcription through PAI-1promoter that was activated by TGFI3 signals. AML1/EVI-1specifically bound to an intracellular signal transducer of TGFβ, Smad3, and inhibited its functions. Because AMLI/EVI-1 bound to a corepressor CtBP, recruitment of histone deacetylase could be an underlying mechanism. AML1/EVI-1 also interfered with AMIL 1-mediated transcription through association with CtBP. Moreover, AML1/EVI-l blocked differentiation of 32D cells induced by G-CSF, depending on the CtBP-binding region in EVI-l portion. These data indicate that AMLI/EVI-1progresses CML or MIDS to acute leukemia partly through abolishing TGFβ signals and blocking AML1 functions.2.We assessed the requirement of AML 1 in adult hematopoiesis using an inducible gene-targeting method. In the absence of AML 1, hematopoietic progenitors were fully maintained with normal myeloid development. However, AML 1-deficient bone marrow showed inhibition of megakaryocytic maturation, increased hematopoietic progenitor cells and defective T-and B-lymphocyte development. These data indicate that AML1 is required for maturation of megakaryocytes and differentiation of T and B cells, but not for maintenance of hematopoietic stem cells in adult hematopoiesis.3.We generated knock-out mice of MEN. They were embryonic lethal, and die before E6.5 and after implantation. MEN was found to play a non-redundant role as an elongation factor in postimplantation development of mice.
期刊论文(132)
专著(0)
科研奖励(0)
会议论文
Waga, K.: "Leukemia-related transcription factor TEL accelerates differentiation of Friend erythroleukemia cells."Oncogene. 22. 59-68 (2003)
Waga, K.:“白血病相关转录因子 TEL 加速 Friend 红白血病细胞的分化。”癌基因。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Nakamura, F.: "Monocytic leukemia with CALM/AF10 rearrangement showing mediastinal emphysema."Am J Hematol. 72. 138-142 (2003)
Nakamura, F.:“单核细胞白血病伴 CALM/AF10 重排,显示纵隔气肿。”Am J Hematol。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Yamagata, T., Mitani, K., Oda, H., Suzuki, T., Honda, H., Asai, T., Maki, K., Nakamoto, T., Hirai, H.: "Acetylation of GATA-3 affects T-cell survival and homing to secondary lymphoid organ."EMBO J. 19. 4676-4687 (2000)
山形,T.,三谷,K.,小田,H.,铃木,T.,本田,H.,浅井,T.,真木,K.,中本,T.,平井,H.:“GATA-的乙酰化-
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Tadokoro, J., Nakamura, Y., Furisawa, S., Mitani K.: "Low frequency of BCL1O gene mutations in B-cell Non-Hodgkin's lymphoma."Int J Hematol. 73. 222-225 (2001)
Tadokoro, J.、Nakamura, Y.、Furisawa, S.、Mitani K.:“B 细胞非霍奇金淋巴瘤中 BCL1O 基因突变的频率较低。”Int J Hematol。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
共 53 条
    Analysis of mechanisms in hematopoietic regulation by transcription factors
    • 批准号:
      20390275
    • 项目类别:
      Grant-in-Aid for Scientific Research (B)
    • 资助金额:
      $10.82万
    • 财政年份:
      2008
    • 负责人:
      MITANI Kinuko
    • 依托单位:
    Molecular mechanism and molecular targeting therapy in transIocation-related leukemia.
    • 批准号:
      17016068
    • 项目类别:
      Grant-in-Aid for Scientific Research on Priority Areas
    • 资助金额:
      $28.54万
    • 财政年份:
      2005
    • 负责人:
      MITANI Kinuko
    • 依托单位:
    Analysis of mechanisms in hematopoietic regulation and leukemia development
    • 批准号:
      17390283
    • 项目类别:
      Grant-in-Aid for Scientific Research (B)
    • 资助金额:
      $8.7万
    • 财政年份:
      2005
    • 负责人:
      MITANI Kinuko
    • 依托单位:
    Mechanisms in hematopoiesis and leukemogenesis by the transcription factor TEL
    • 批准号:
      14370308
    • 项目类别:
      Grant-in-Aid for Scientific Research (B)
    • 资助金额:
      $7.81万
    • 财政年份:
      2002
    • 负责人:
      MITANI Kinuko
    • 依托单位:
    国内基金
    海外基金
    EVI-1诱导miR-124甲基化通过RAS/ERK通路调控AML发生发展的机制研究
    • 批准号:
      82000148
    • 项目类别:
      青年科学基金项目
    • 资助金额:
      24.0万元
    • 批准年份:
      2020
    • 负责人:
      郎雯竞
    • 依托单位:
    EVI-1/NM IIA/MG53通路在急性肾小管损伤中的作用研究
    • 批准号:
      81700604
    • 项目类别:
      青年科学基金项目
    • 资助金额:
      20.0万元
    • 批准年份:
      2017
    • 负责人:
      于晓文
    • 依托单位:
    Evi-1、microRNA和DNA甲基化的调控环路异常导致白血病预后不良的机制研究
    • 批准号:
      81170517
    • 项目类别:
      面上项目
    • 资助金额:
      14.0万元
    • 批准年份:
      2011
    • 负责人:
      王莉莉
    • 依托单位: